Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria.
10.19746/j.cnki.issn.1009-2137.2021.05.036
- Author:
Jia-Ying WU
1
;
Fan-Kai MENG
1
;
Yang CAO
1
;
Jin-Huan XU
1
;
Li-Fang HUANG
1
;
Na WANG
1
;
Dong-Hua ZHANG
1
;
Yi-Cheng ZHANG
1
;
Jian-Feng ZHOU
1
;
Yi XIAO
2
Author Information
1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
2. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China,E-mail: yixiao@tjh.tjmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Anemia, Aplastic/therapy*;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Hemoglobinuria, Paroxysmal/therapy*;
Humans;
Transplantation Conditioning
- From:
Journal of Experimental Hematology
2021;29(5):1601-1605
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for paroxysmal nocturnal hemoglobinuria (PNH), and preliminarily explore the role of an improved post-transplantation cyclophosphamide (PTCy) based conditioning regimen in PNH patients receiving transplantation.
METHODS:Clinical related data of PNH sufferers receiving allo-HSCT in Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology were collected, and hematopoietic reconstitution, chimerism, PNH cloning, graft-versus-host disease (GVHD), infection, and survival were analyzed.
RESULTS:Totally five PNH patients receiving allo-HSCT were enrolled, including 1 case with classic PNH, 3 cases with aplastic anemia-PNH syndrome, 1 case with myelodysplastic syndrome, three of them (case 1-3) received the improved PTCy based conditioning regimen before HSCT. All sufferers engrafted successfully within 28 days, the median time of neutrophil and platelet engraftment was 11 days and 12 days, respectively, no patient occurred acute or chronic GVHD, after a median follow-up of 16 months, all recipients survived and completely eliminated PNH cloning.
CONCLUSION:Allo-HSCT can completely clear PNH cloning and restore hematopoietic function with controllable complications, and the improved PTCy based conditioning regimen is proved to be effective in PNH transplantation.
